Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT02277769. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).
Study identification
- NCT ID
- NCT02277769
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 708 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014 (Actual)
- Primary completion
- Oct 31, 2015 (Actual)
- Completion
- Jan 31, 2016 (Actual)
- Last update posted
- Jun 2, 2020
2014 – 2016
United States locations
- U.S. sites
- 53
- U.S. states
- 27
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Anniston | Alabama | — | — |
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Bakersfield | California | — | — |
| Not listed | Costa Mesa | California | — | — |
| Not listed | Fremont | California | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | Roseville | California | — | — |
| Not listed | Temecula | California | — | — |
| Not listed | Trumbull | Connecticut | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Oviedo | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | West Palm Beach | Florida | — | — |
| Not listed | Alpharetta | Georgia | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Columbus | Georgia | — | — |
| Not listed | Buffalo Grove | Illinois | — | — |
| Not listed | Plainfield | Indiana | — | — |
| Not listed | West Des Moines | Iowa | — | — |
| Not listed | Overland Park | Kansas | — | — |
| Not listed | Rockville | Maryland | — | — |
| Not listed | Washington Park | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Farmington Hills | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Plymouth | Minnesota | — | — |
| Not listed | Saint Joseph | Missouri | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Billings | Montana | — | — |
| Not listed | Bozeman | Montana | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Verona | New Jersey | — | — |
| Not listed | Forest Hills | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Smithtown | New York | — | — |
| Not listed | Chapel Hill | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Jenkintown | Pennsylvania | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Bellaire | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02277769, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2020 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02277769 live on ClinicalTrials.gov.